Jeff Albers | CEO |
Mike Landsittel | CFO |
Christy Rossi | CCO |
Fouad Namouni | President, R&D |
Becker Hewes | CMO |
Kristin Hodous | IR |
Andrea Tan | Goldman Sachs |
Reni Benjamin | JMP Securities |
Dane Leone | Raymond James |
Marc Frahm | Cowen and Company |
Andrew Berens | SVB Leerink |
Avatar Jones | Morgan Stanley |
Arlinda Lee | Canaccord Genuity Inc. |
Paul Jeng | Guggenheim Securities |
Benjamin Kallo | Robert W. Baird |
Peter Lawson | Barclays |
David Nierengarten | Wedbush Securities |
Brad Canino | Stifel Financial Corp. |
Good morning. My name is Maxine, and I will be your conference operator today. At this time, I would like to welcome everyone to the Blueprint Medicines’ 3Q 2021 Financial Results Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session.